Docket Number:12A-981111
Inventor:Mi-Hua Tao, Cheng-Chieh Fang, Ya-Hui Huang
IP Status:Issued US8,383,879、TW I503413
Abstract:
- Our HBV disease mouse model is the first mouse model that can recapitulate many pathological changes of HBV-related liver diseases, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
- Our HBV disease mouse model can be used to evaluate the efficacy of various anti-HBV drugs in prevention and/or therapy of HBV-related liver diseases at early and/or late stages. Our animal model is particularly useful for testing the efficacy of immunomodulators, including herbal medicine, because the HBV-induced immune hyporesponsiveness in these mice is very similar to that in natural HBV infection in humans.
- Our HBV disease mouse model is useful in identifying host and viral factors involving in initiation and maintenance of HBV-related liver diseases. These host and viral factors could serve as good targets for developing molecular-targeting drugs.
Fields of Application:
Development of drugs for chronic HBV infection and hepatocellular carcinoma.
Advantages when compared to the existing technologies:
Our HBV disease mouse model is the first and only mouse model that can recapitulate many pathological changes of HBV-related liver diseases. Chimpanzees are susceptible to HBV infections, but usually do not develop chronic liver diseases and are costly to use. HBV-related viruses in woodchuck and ground squirrels can induce hepatocellular carcinoma but their molecular mechanisms are different from HBV-associated liver cancers in humans. HBV transgenic mice are centrally immune tolerant to HBV proteins and do not develop liver diseases. Hydrodynamic injection of a full-length HBV genome into immune competent mice can generate transient or long-term HBV replication in the liver, but do not cause liver diseases.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
